Check the time stamp on this data. Updated AI-Generated Signals for Iovance Biotherapeutics Inc. (IOVA) available here: IOVA.

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Iovance Biotherapeutics (IOVA – Research ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying ...

Iovance Biotherapeutics Inc (IOVA) stock saw a decline, ending the day at $6.19 which represents a decrease of $-0.06 or -0.96% from the prior close of $6.25. The stock opened at $6.28 and touched a ...

SG Americas Securities LLC purchased a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund purchased 69,625 ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that ...

Truist Securities confirmed its positive stance on Iovance Biotherapeutics (NASDAQ:IOVA) shares, maintaining a Buy rating and a price target of $25.00. With the stock currently trading at $6.07, this ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...